基线IsoPSA指数低与前列腺特异性抗原升高男性临床显著性前列腺癌诊断长期低风险相关
单中心回顾性研究纳入2016年11月至2022年8月接受IsoPSA检测的1578例患者,按基线IsoPSA指数≤6与>6分组。低指数组后续活检临床显著性前列腺癌(csPCa)诊断率为4.3%,高指数组为35.3%;30个月时csPCa风险低指数组为6.3%,高指数组为49.5%。
要点
- 基线IsoPSA≤6组后续活检csPCa诊断率4.3%,>6组为35.3%。
- 30个月csPCa风险低指数组6.3%,高指数组49.5%。
- 作者认为结果支持用IsoPSA安全地避免后续检测。
核心结论
- 初始IsoPSA指数低的患者在未来30个月内发生csPCa的风险小于初始IsoPSA指数高的患者,支持使用IsoPSA安全地避免后续检测。
研究设计与样本
- 单中心回顾性审查2016年11月至2022年8月连续接受IsoPSA检测的患者1578例,按基线IsoPSA指数≤6与>6二分类。
主要发现
- 541例初始IsoPSA指数≤6患者中23例(4.3%)后续活检诊断为csPCa;该541例中204例接受MRI,48/204(23.5%)显示可疑病灶(PIRADS≥4)。
- 1037例初始IsoPSA指数>6患者中366例(35.3%)后续活检诊断为csPCa;该1037例中712例接受MRI,342/712(48.0%)显示可疑病灶(PIRADS≥4)。
- 12、24、30个月时低IsoPSA指数组发生csPCa的风险分别为0.4%(95%CI 0.1%-1.6%)、2.5%(95%CI 1.4%-4.4%)、6.3%(95%CI 4%-9.6%)。
- 12、24、30个月时高IsoPSA指数组发生csPCa的风险分别为5.9%(95%CI 4.6%-7.6%)、31.7%(95%CI 28.3%-35.4%)、49.5%(95%CI 45.3%-53.9%)。
临床怎么用
- 作者认为结果支持使用IsoPSA安全地避免后续检测。
局限性
- 局限性包括对前瞻性收集数据进行回顾性审查,以及并非所有患者均接受活检、真实csPCa发生率未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the rate of diagnosing clinically significant prostate cancer (csPCa) in men with elevated prostate-specific antigen (PSA) stratified by baseline IsoPSA Index, thus assessing IsoPSA's intermediate-term predictive ability for csPCa. MATERIAL AND METHODS: Single-center retrospective review of consecutive patients (n = 1578) who underwent IsoPSA testing from November 2016-August 2022. Data dichotomized into patients with low (≤6) and high IsoPSA Indices (>6). Most recent subsequent IsoPSA and PSA tests, prostate biopsy, and magnetic resonance imaging (MRI) collected. Time-to-event Kaplan-Meier estimates generated for the risk of csPCa stratified by baseline IsoPSA Index. RESULTS: Among 541 patients with initial low IsoPSA Indices (≤6), 23 (4.3%) were diagnosed with csPCa on a subsequent biopsy. Also, among these 541 patients, 204 had an MRI, of which 48/204 (23.5%) showed suspicious lesions (PIRADS ≥4). Among 1037 patients with initial high IsoPSA Indices, 366 (35.3%) were diagnosed with csPCa on a subsequent biopsy. Also, among these 1037 patients, 712 had an MRI, of which 342/712 (48.0%) showed suspicious lesions (PIRADS ≥4). After 12, 24, and 30 months, respectively, the risk of developing csPCa was 0.4% (95% CI 0.1%-1.6%), 2.5% (1.4%-4.4%), and 6.3% (4%-9.6%) in patients with low IsoPSA Indices, compared to 5.9% (4.6%-7.6%), 31.7% (28.3%-35.4%), and 49.5% (45.3%-53.9%) in patients with high IsoPSA Indices. Limitations include the retrospective review of prospectively collected data and unknown true csPCa rates as not all patients were biopsied. CONCLUSION: The risk of developing csPCa was smaller in patients with initial low vs high IsoPSA Indices over the ensuing 30 months, which supports using IsoPSA to safely avoid follow-up testing.
引用
- Abdallah N, Campbell RA, Benidir T, et al. Low Baseline IsoPSA Index is Associated With a Prolonged Low Risk of Clinically Significant Prostate Cancer Diagnosis in Men With an Elevated PSA. Urology. 2025. PMID: 39824364. doi:10.1016/j.urology.2025.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。